Two more Russian vaccines: What we do and don t know
Russia has approved three coronavirus vaccines first, Sputnik-V, then EpiVacCorona and CoviVac. But clinical trials for the last two are incomplete.
Russia wants to produce 50 million vaccine sets by May
Russia wants the majority of its citizens to be vaccinated against the novel coronavirus, SARS-CoV-2, by the autumn of 2021. And it appears to be pushing three homegrown vaccines to meet that goal at all costs.
All three of those vaccines have been approved prior to completing large-scale phase 3 clinical trials an internationally recognized scientific standard that aims to ensure the safety and efficacy of vaccines.
COVID Vaccine Makers to Congress: Expect Steady Rise in US Supply medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
comments
Assuming that the paperwork all goes as planned, the United States will likely have three novel coronavirus vaccines available by late spring: the Moderna vaccine, the Pfizer vaccine, and the forthcoming Oxford University/AstraZeneca vaccine, which is already being distributed in the United Kingdom and will soon face regulatory scrutiny here.
Many Americans don t have a choice as to which vaccine they get: their health care provider issues whatever they have on hand. Yet as time goes on and scarcity diminishes, some of us might actually be faced with a choice. That raises a curious question: With so many vaccines available to the public, which one should patients opt for if they do have the choice?
There is particular interest in monoclonal antibody agents to determine whether their immune suppressive effects can reduce the immediate and long-term impact of COVID-19.